Cramer's week ahead: The most important week of earnings season
- ByCNBC-
"This is the toughest week of the quarter when it comes to making informed financials decisions," CNBC's Jim Cramer said ahead of reports from Apple and others.
"This is the toughest week of the quarter when it comes to making informed financials decisions," CNBC's Jim Cramer said ahead of reports from Apple and others.
Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints...
Discussion and analysis on my top five stocks for July 2021: BMY, ENB, HBAN, LMT and PNW.
Both companies have the same yield, at right about 2.9%. They've also both been increasing their dividends for almost the same exact length of time - 12 years for Bristol-Myers...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1,569.00 | 1,572.50 | 1,547.50 | +25.00 | +1.62% | 933.10K | London | |||
| 140.40 | 142.75 | 138.90 | +2.30 | +1.67% | 6.31M | London | |||
| 48.04 | 50.02 | 47.94 | -1.26 | -2.56% | 26.66M | London | |||
| 740.00 | 742.60 | 731.60 | +8.00 | +1.09% | 475.98K | London | |||
| 869.50 | 879.00 | 862.00 | +11.00 | +1.28% | 826.06K | London | |||
| 401.60 | 404.95 | 400.10 | +0.90 | +0.23% | 8.86M | London | |||
| 266.50 | 269.20 | 265.00 | -1.40 | -0.52% | 5.43M | London | |||
| 745.20 | 766.20 | 743.60 | -12.80 | -1.69% | 878.66K | London | |||
| 125.60 | 125.80 | 118.50 | +4.50 | +3.72% | 2.98M | London | |||
| 276.60 | 277.90 | 273.00 | +6.10 | +2.25% | 1.44M | London | |||
| 18.25 | 18.40 | 17.50 | +0.50 | +2.82% | 5.66M | London | |||
| 673.00 | 678.00 | 672.00 | +1.20 | +0.18% | 1.24M | London | |||
| 1,416.00 | 1,419.20 | 1,406.40 | +6.40 | +0.45% | 3.13M | London | |||
| 45.88 | 46.07 | 45.36 | +0.66 | +1.45% | 77.42M | London | |||
| 585.00 | 600.00 | 585.00 | 0.00 | 0.00% | 40.78K | London |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.